Journal: *Drugs - Real World Outcomes*

Article title: Real-World Utilization and Safety of Daratumumab IV Rapid Infusions Administered in a Community Setting: A Retrospective Observational Stu**dy**

Running head: Real-world utilization of daratumumab rapid infusions

Authors: Lucio Gordan, MD[1]; Melody Chang, RPh[1]; Marie-Hélène Lafeuille, MA[2]; Hela Romdhani, PhD[2]; Fuad Paramasivam, BA[2]; Eric M. Maiese, PhD[3], Caroline McKay, PhD[3]

[1] Florida Cancer Specialists, Gainesville Florida, United States
[2] Analysis Group, Inc., Montreal Quebec, Canada
[3] Janssen Scientific Affairs, LLC, Horsham New Jersey, United States

Corresponding author email: Marie-Helene.Lafeuille@analysisgroup.com

Supplemental Table 1. Non-infusion reaction adverse events[a]

	N = 147	
Number of patients with ≥1 non-IR AE, n (%)	**15**	**(10.2%)**
Number of non-IR AEs per patient,[b] mean ± SD [median; IQR]	**1.9**	**± 1.2 [2;2]**
Non-IR AEs, n (%)		
Gastrointestinal toxicities	4	(2.7%)
Constipation	1	(0.7%)
Diarrhea	1	(0.7%)
Nausea	2	(1.4%)
Vomiting	2	(1.4%)
General disorders and administration site conditions	8	(5.4%)
Fatigue	8	(5.4%)
Pyrexia	1	(0.7%)
Edema peripheral	0	(0.0%)
Chills	0	(0.0%)
Laboratory abnormalities	1	(0.7%)
Anemia	0	(0.0%)
Cytopenia	0	(0.0%)
Lymphopenia	0	(0.0%)
Neutropenia	1	(0.7%)
Thrombocytopenia	0	(0.0%)
Metabolism and nutrition disorder	1	(0.7%)
Decreased appetite	1	(0.7%)

Musculoskeletal and connective tissue disorders	2	(1.4%)
Muscle spasms	1	(0.7%)
Back pain	0	(0.0%)
Arthralgia	1	(0.7%)
Musculoskeletal chest pain	0	(0.0%)
Nervous system disorder	0	(0.0%)
Headache	0	(0.0%)
Peripheral sensory neuropathy	0	(0.0%)
Respiratory, thoracic and mediastinal disorders	0	(0.0%)
Cough	0	(0.0%)
Dyspnea	0	(0.0%)
Nasal congestion	0	(0.0%)
Vascular disorder	0	(0.0%)
Hypertension	0	(0.0%)
Hypotension	0	(0.0%)
Thrombosis	0	(0.0%)
Congestive heart failure	0	(0.0%)
Renal toxicities	0	(0.0%)
Other[c]	6	(4.1%)

Abbreviations: AE: adverse event; IQR: interquartile range; IR: infusion reaction; SD: standard deviation.

Notes:

a. AEs were defined as health events explicitly attributed to daratumumab in the patient charts that did not also meet the definition of an infusion reaction.
b. Among patients with at least one AE.
c. The following other symptoms were reported: nosebleeds, GI bleeding, shakiness, dizziness, aches and pain, and abdominal pain.